Table 4.

Multivariate Competing RRisk Analyses Evaluating Predictors of Death After Liver Transplantation.

						Pre-DAA Era				Post-DAA Era
		HR	95% CI		p	HR	95% CI		p	HR	95% CI		P
Gender	Male	1				1				1
	Female	0.97	0.94	0.99	0.01	0.97	0.94	1.00	0.07	0.92	0.85	1.00	0.04
Ethnicity	White	1				1				1
	Black	1.16	1.11	1.21	<0.001	1.16	1.11	1.22	<0.001	1.16	1.03	1.31	0.01
	Hispanic	0.88	0.84	0.92	<0.001	0.87	0.83	0.91	<0.001	0.96	0.86	1.08	0.53
	Asian	0.73	0.68	0.79	<0.001	0.72	0.66	0.77	<0.001	0.84	0.68	1.02	0.08
HCV	No	1				1				1
	Yes	1.17	1.14	1.21	<0.001	1.20	1.17	1.24	<0.001	0.97	0.89	1.06	0.49
HCC	No	1				1				1
	Yes	1.15	1.11	1.19	<0.001	1.17	1.13	1.22	<0.001	1.07	0.97	1.19	0.17
Diabetes	No	1				1				1
	Yes	1.32	1.28	1.36	<0.001	1.33	1.29	1.37	<0.001	1.26	1.16	1.36	<0.001
Era	Pre-DAA	1
	Post-DAA	0.68	0.66	0.71	<0.001
Age at listing		1.02	1.02	1.02	<0.001	1.02	1.02	1.02	<0.001	1.01	1.01	1.02	<0.001
BMI at transplant		0.99	0.99	0.99	<0.001	0.99	0.99	0.99	<0.001	0.99	0.98	1.00	0.01
Biologic MELD at transplant		1.01	1.01	1.02	<0.001	1.01	1.01	1.01	<0.001	1.02	1.02	1.02	<0.001

DAA = direct-acting antiviral; HR = hazard ratio; CI = confidence interval; BMI = body mass index; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; UNOS = United Network for Organ Sharing.

Model adjusted for demographics, HCV status, HCC status, diabetes, treatment era, BMI, biologic MELD at transplant, age at listing, and UNOS region.